Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

NCT01463059 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: Olokizumab 60 mg
BIOLOGICAL: Olokizumab 120 mg
BIOLOGICAL: Olokizumab 240 mg

Sponsor

UCB Japan Co. Ltd.